Compare Johnson & Johnson (JNJ) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kaltura Inc — how do they compare? Johnson & Johnson trades at $260.45 (market cap $618.09B), while Kaltura Inc trades at $1.31 (market cap $199.08M). The key difference: Johnson & Johnson is far larger — about 3104.7× Kaltura Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Kaltura Inc for 21 Days on average.
| JNJ | KLTR | |
|---|---|---|
Market Cap | $618.09B | $199.08M |
Volume | 6,050,983 | 175,927 |
Sector | Health | Technology |
52-Week High | $278.43 | $1.89 |
52-Week Low | $186.00 | $1.08 |
Typical Hold Time | 129 Days | 21 Days |
Enterprise Value | $646.37B | $211.29M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Kaltura (KLTR) trades at $1.305, down 1.88% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent positive developments include AI platform awards and major streaming deployments, though valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The stock presents a turnaround story with improving profitability trends but faces significant execution risks. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term pressure. Key catalysts include AI product commercialization and further margin improvement, but high debt levels and persistent losses require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
